The 4 most recent market catalysts affecting $VBIO, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Sep 23, 2026
Corporate Catalyst
Neutral
Impact 75
Valion Bio Appoints Dean Zikria Interim CEO, Thomas Jensen As Board Chair
Valion Bio has announced a significant shake-up in its executive leadership and Board of Directors. Dean Zikria, a current board member, has been appointed Interim CEO, tasked with…
Aug 27, 2026
Corporate Catalyst
Neutral
Impact 65
Valion Bio Announces 1-For-25 Reverse Stock Split, Effective Aug. 31
Valion Bio announced a 1-for-25 reverse stock split, effective August 31, 2026, to meet the Nasdaq Capital Market's minimum bid price requirement. This action, while necessary to m…
Jul 22, 2026
Corporate Catalyst
Bullish
Impact 65
Ukraine's Ministry Of Health Accepts Valion Bio's Regulatory Dossier For Entolimod For Formal Review Under Regulatory Equivalence Pathway
Valion Bio announced that Ukraine's Ministry of Health (MoH) has accepted its regulatory dossier for Entolimod, a medical countermeasure for Acute Radiation Syndrome (ARS), for for…
Jul 20, 2026
Corporate Catalyst
Bullish
Impact 65
Valion Bio To Carry Out Study At Sheba Medical Center To Mull Entolimod In 10 Cancer Participants
Valion Bio (VBIO) has announced a significant clinical development: a collaboration with Sheba Medical Center to conduct a clinical trial for Entolimod in cancer patients undergoin…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.